Form 4: Centessa Pharmaceuticals CEO Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Centessa Pharmaceuticals CEO, Saurabh Saha, executed multiple sales of ordinary shares and exercised stock options over several days, according to a recent SEC Form 4 filing.
Summary
- Centessa Pharmaceuticals CEO, Saurabh Saha, has sold a total of 60,182 ordinary shares between November 20, 2024 and November 22, 2024.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 16, 2024.
- The sales occurred at weighted average prices ranging from $16.8858 to $18.2396 per share.
- Saha also exercised options to acquire 5,182 ordinary shares at an exercise price of $5.84 per share.
- Following these transactions, Saha directly owns 575,661 ordinary shares and indirectly owns 38,000 shares through a trust.
- He also holds options to purchase 3,957,280 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing share sales by the CEO under a pre-arranged plan. It doesn't indicate any positive or negative sentiment, but the market may react to the sales.
Risks
- The CEO's share sales, even under a pre-arranged plan, could be perceived negatively by the market.
- The market may interpret the sales as a lack of confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions and is common for publicly traded companies. It does not indicate any specific industry trend or competitive activity.
Comparison to Industry Standards
- SEC Form 4 filings are standard practice for publicly traded companies, and the transactions reported are typical for executives with stock options and pre-arranged trading plans.
- The use of a 10b5-1 trading plan is a common method for insiders to sell shares without raising concerns about insider trading.
Stakeholder Impact
- Shareholders may react to the CEO's share sales, potentially impacting the stock price.
- The sales do not directly impact employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 11/20/2024 | Date of the first reported sale of ordinary shares. |
| 11/21/2024 | Date of option exercise and sale of ordinary shares. |
| 11/22/2024 | Date of option exercise and sale of ordinary shares. |
| 02/19/2022 | Date when 25% of the shares subject to the option became exercisable. |
| 02/19/2031 | Expiration date of the share options. |
Keywords
Centessa Pharmaceuticals, Saurabh Saha, SEC Form 4, share sales, stock options, Rule 10b5-1, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.